Heron Therapeutics (NASDAQ:HRTX) Stock, Quote.Headers.trade-ideas

Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Earnings

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ARGX

ARQT

HRTX

Shares of Argenx (NASDAQ: ARGX) rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart Hytrulo (efgartigimod) for a second indication — chronic inflammatory demyelinating polyneuropathy (CIDP).

FDA Expands Argenx&#39;s Vyvgart Label to Treat Rare Disorder

Biotech

MRNS

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.

Avidity Up 33% on Rare Muscle Disease Study Results

Monitoring,Of,Patient's,Heart,In,Intensive,Care,Unit.

Short Ideas

Pre-Market Outlook

CDNA

TMDX

Top 3 Health Care Stocks That May Crash In May

Heron Therapeutics Inc

Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And Potential To Reduce Opioid Use

-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024
SAN DIEGO, July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF&#xAE; (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.
If approved, the introduction of the VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time from up to three minutes down to between twenty and forty-five seconds. The user-friendly "container-like" design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. If approved, the VAN is expected to be available for use in the fourth quarter of this year.

Heron Therapeutics Announces The FDA Acknowledged The Receipt Of The Company's Prior Approval Supplement Application For ZYNRELEF

Rodman &amp; Renshaw analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy rating and announces Price Target of $7.

Price Target

Initiation

Rodman & Renshaw Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $7

Heron Therapeutics Announces Prior Approval Supplement Submission To FDA For ZYNRELEF VAN

As of May 24, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>On April 30, TransMedics posted upbeat quarterly results and raised its 2024 guidance. &#8220;We are pleased with our first quarter results as we simultaneously drove continued revenue growth, expanded our infrastructure, and achieved profitability,&#8221; said Waleed Hassanein, MD, President and Chief Executive Officer. The company's stock gained around 55% over the past month and has a <a href="https://www.benzinga.com/quote/TMDX">52-week high of $142.30</a>.</li>
<li>RSI Value: 78.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TMDX Price Action: Shares of TransMedics rose 0.4% to close at $137.53 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</h3>
<ul>
<li>On May 9, CareDX reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates. &#8220;We set a new baseline in our Testing Services business in the second half of 2023 and are back to delivering sequential growth. I am pleased with the team&#8217;s strong performance across all businesses this quarter,&#8221; said John W. Hanna, CareDx President and CEO. The company's stock gained around 98% over the past month and <a href="https://www.benzinga.com/quote/CDNA">has a 52-week high</a> of $16.54.</li>
<li>RSI Value: 76.48</li>
<li>CDNA Price Action: Shares of CareDx rose 1.7% to close at $15.83 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>)</h3>
<ul>
<li>On May 7, Heron Therapeutics reported better-than-expected first-quarter financial results and reaffirmed its FY24 revenue guidance. &#8220;We are extremely pleased with our ability to improve the financial efficiency of the business by growing revenues, improving margins, and reducing expenses. We made tremendous progress this quarter by promptly training CrossLink sales representatives and integrating them into our commercial execution, while also training our own commercial team on the newly expanded label for ZYNRELEF,&#8221; said Craig Collard, Chief Executive Officer of Heron. The company's stock gained around 31% over the past month and has a <a href="https://www.benzinga.com/quote/HRTX">52-week high</a> of $3.59.</li>
<li>RSI Value: 71.77</li>
<li>HRTX Price Action: Shares of Heron Therapeutics closed at $3.47 on Thursday.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/24/05/38984382/slb-first-solar-and-2-other-stocks-insiders-are-selling">SLB, First Solar And 2 Other Stocks Insiders Are Selling</a>

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $5 price target.

Reiteration

Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target

Guidance

Heron Therapeutics Reaffirms FY24 Revenue $138.0M-$158.0M Vs $144.875M Est.

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.09) by 77.78 percent. The company reported quarterly sales of $34.700 million which beat the analyst consensus estimate of $32.975 million by 5.23 percent. This is a 17.17 percent increase over sales of $29.615 million the same period last year.

Earnings Beats

Heron Therapeutics Q1 2024 GAAP EPS $(0.02) Beats $(0.09) Estimate, Sales $34.700M Beat $32.975M Estimate

Shares of Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/04/38365860/nucor-shares-fall-after-worse-than-expected-q1-results">quarterly financial results</a>.
Nucor reported quarterly earnings of $3.46 per share which missed the analyst consensus estimate of $3.65. Quarterly sales came in at $8.14 billion, missing the analyst consensus estimate of $8.26 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Nucor shares tumbled 6.5% to $179.20 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares jumped 100% to $0.2419 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares climbed 50.4% to $0.0689 after falling 10% on Monday.</li>
<li>Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) gained 46% to $3.29 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 44.3% to $7.12 after the company entered a collaboration with Strand Life Sciences.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) gained 27% to $0.5683 after the company announced it delivered on an immediate basis, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) climbed 20% to $5.22.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 19.5% to $1.5307 after declining 3% on Monday.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) gained 18.7% to $9.49.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) rose 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 17.4% to $1.3499.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) rose 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) gained 15.5% to $0.9295.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) climbed 15.2% to $2.20.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares gained 15% to $0.2244 after the company announced new preclinical data will be presented at the American Society of Gene and Cell Therapy meeting.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) jumped 14.4% to $0.8603.</li>
<li>9F Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFU#NASDAQ">JFU</a>) rose 14.3% to $3.29.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) gained 14% to $1.05. The company executives announced intentions to purchase at least $2 million of the company's common stock.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) jumped 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) climbed 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 9.4% to $6.05.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) rose 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 8.8% to $10.15.</li>
<li>HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) surged 7.4% to $25.91 following upbeat quarterly results.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 7% to $0.55 following upbeat quarterly results.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) gained 6.2% to $62.20.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 48.4% to $3.7950 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares fell 44.6% to $0.0699. Greenwave Technology Solutions disclosed that it further strengthened its balance sheet by approximately $12 million.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) fell 44.4% to $0.5450.</li>
<li>Tungray Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares declined 34.2% to $4.87 after gaining 24% on Monday.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 26.3% to $0.5091.</li>
<li>Moolec Science SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) fell 24.3% to $1.87. On April 22, Moolec Science said it received approval for its plant-grown animal proteins.</li>
<li>YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) fell 22.4% to $2.25 after tumbling over 27% on Monday. The company, last week, priced its IPO at $4 per share.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) dipped 19.7% to $2.0899.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) declined 18.8% to $6.44.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) dipped 18% to $0.2369. SuperCom recently reported better-than-expected quarterly results.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) declined 16.2% to $6.29 after the company reported first-quarter financial results and issued worse-than-expected Q2 and FY24 Revenue outlook.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) declined 13% to $448.01 following first-quarter financial results.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.6% to $42.78 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
<li>Simpson Manufacturing Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) dipped 11.7% to $163.40 following weak quarterly earnings.</li>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 11.2% to $0.1598 after the company filed for a mixed shelf offering of up to $75 million.</li>
<li>Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) tumbled 11.1% to $14.60 after the company reported worse-than-expected first-quarter results and reiterated FY24 guidance.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) declined 10.4% to $2.83 after gaining around 7% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) shares fell 10.1% to $7.13 after the company issued its production and sales performance metrics for the nine months ended 31 March, 2024.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) fell 9.3% to $0.3530 after dipping around 14% on Monday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) dipped 7.8% to $19.22 after the company&#8217;s reported worse-than-expected first-quarter financial results.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 7.1% to $0.77. Phio Pharmaceuticals shares jumped around 33% on Monday after the company announced that its intratumoral injection of murine PH-762 inhibited tumor growth in murine tumor models and may generate memory-specific T cells.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) shares fell 4.1% to $28.34 after the company reported mixed first-quarter financial results and issued second-quarter guidance below estimates.</li>
</ul>
Read More: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38379861/bitcoin-surpasses-66-000-akash-network-core-among-top-gainers">Bitcoin Surpasses $66,000; Akash Network, Core Among Top Gainers</a>

Intraday Update

Movers

ABEO

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HIBB

HSTM

JAGX

JBLU

KULR

LICN

MESO

MLEC

MSCI

OPRT

PALI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

TTOO

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday.
Shares of HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) rose sharply during Tuesday's session following upbeat <a href="https://www.benzinga.com/quote/HSTM/earnings">quarterly results</a>.
HealthStream posted first-quarter GAAP earnings of 17 cents per share, beating market estimates of 11 cents per share. The company's quarterly sales came in at $72.760 million versus expectations of $71.883 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
HealthStream shares jumped 7.4% to $25.91 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares gained 29% to $2.03.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares jumped 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 15.5% to $0.9295.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) climbed 14.2% to $1.3150.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) gained 14.4% to $0.8603.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) rose 14.2% to $10.30. Critical Metals named Tony Sage as Chief Executive Officer.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) surged 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) shares jumped 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) gained 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) rose 10.3% to $22.42.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) climbed 9.6% to $172.59 as life sciences stocks gained following strong earnings from Danaher.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) surged 9.4% to $6.05.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 9.2% to $783.26.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) climbed 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 8.8% to $10.15.</li>
<li>Lifezone Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) gained 8.4% to $7.26.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) rose 8.1% to $10.86.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) surged 8.1% to $19.00.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) rose 7.4% to $140.70 after the European Commission approved Tislelizumab for non-small cell lung cancer across three indications, including first- and second-line use.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 7% to $252.49 following better-than-expected first-quarter financial results.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) gained 6.6% to $172.15.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares jumped 6.2% to $62.20.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/04/38376714/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 3% Dividend Yields</a>

BGNE

CRML

MARA

RGEN

SMCI

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday

WIIM

Heron Therapeutics shares are trading higher after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.

Capital One analyst Tim Chiang initiates coverage on Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Overweight rating and announces Price Target of $6.

Capital One Initiates Coverage On Heron Therapeutics with Overweight Rating, Announces Price Target of $6

Tuesday,&nbsp;Heron Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported a fourth-quarter 2023 EPS of $(0.07), beating the consensus of $(0.16).
Sales increased 14% Y/Y to $34.23 million, beating the consensus of $30.98 million due to stronger upticks in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37633659/heron-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-highlights-re" rel="noreferrer noopener">Zynrelef, Cinvanti, and Sustol</a>.
&#8220;In the fourth quarter of 2023, Heron saw continued positive momentum and an increased sales trajectory in both our acute care and oncology care franchises, illustrating how the strategic decisions made over the past year have positioned the Company for long-term success and profitability,&#8221; said Craig Collard, Chief Executive Officer of Heron.&nbsp;
Acute Care Franchise sales increased from $3.9 million to $6.1 million in the fourth quarter of 2023.
Oncology Care Franchise sales reached $28.1 million versus $26.1 million a year ago.&nbsp;
Guidance:&nbsp;Heron Therapeutics expects fiscal year 2024 product revenues of $138 million-$158 million, with adjusted EBITDA of $(22.0) million-$3.0 million.
The strong finish to 2023 is expected to bolster confidence in the company&#8217;s ability to achieve its revenue target of $138 million to $158 million and its target to achieve positive adjusted EBITDA.
Needham&nbsp;maintains its Buy rating on the company&#8217;s stock and revises the price target upward from $4 to $5 to reflect adjustments in financial models and recent sales trends.&nbsp;
The analysts anticipate that it may take several quarters of improved sales performance to demonstrate significant progress toward achieving the envisioned level of profitability.
Price Action: HRTX shares are up 30.1% at $3.07 on the last check Wednesday.

Analyst Color

Equities

Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?

<h3>Gainers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock rose 34.56% to $0.52. The market value of their outstanding shares is at $23.8 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 34.32% to $0.52. The company's market cap stands at $27.2 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares moved upwards by 33.01% to $0.11. The market value of their outstanding shares is at $4.3 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares increased by 27.9% to $5.73. The company's market cap stands at $256.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares increased by 26.36% to $5.8. The company's market cap stands at $453.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares fell 22.6% to $26.24 during Wednesday's regular session. The market value of their outstanding shares is at $31.6 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 22.0% to $1.13. The company's market cap stands at $2.7 million. The company's, Q4 earnings came out yesterday. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock declined by 21.49% to $0.8. The market value of their outstanding shares is at $92.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock fell 20.4% to $6.05. The company's market cap stands at $118.2 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) stock fell 18.28% to $14.18. The company's market cap stands at $2.2 billion. The company's, Q4 earnings came out 4 days ago. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock declined by 16.28% to $0.36. The market value of their outstanding shares is at $17.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANNX

Envoy Medical, Inc. - Class A Common Stock

COCH

CRDF

Kintara Therapeutics, Inc. - Common Stock

KTRA

MEDS

NCNA

NMRA

PIII

TCON

TNON

12 Health Care Stocks Moving In Wednesday's Intraday Session

Heron therapeutics shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $4 to $5.

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and raises the price target from $4 to $5.

Needham Maintains Buy on Heron Therapeutics, Raises Price Target to $5

Heron therapeutics shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance.

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Heron Therapeutics beat estimated earnings by 56.00000000000001%, reporting an EPS of $-0.07 versus an estimate of $-0.16.
Revenue was up $4.21 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.12 which was followed by a 59.0% increase in the share price the next day.
Here's a look at Heron Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.23</td>
<td>-0.20</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.35</td>
<td>-0.27</td>
<td>-0.17</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>32.75M</td>
<td>31.70M</td>
<td>29.69M</td>
<td>26.90M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>31.43M</td>
<td>31.76M</td>
<td>29.61M</td>
<td>30.03M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Heron Therapeutics <a href="https://www.benzinga.com/quote/HRTX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Heron Therapeutics: Q4 Earnings Insights

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Heron Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hrtx-stock-quote/">HRTX</a>) just reported results for the first quarter of 2024.<ul><li>Heron Therapeutics reported earnings per share of -2 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company reported revenue of $34.67 million.</li><li>This was 5.70% better than the analyst estimate for revenue of $32.80 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/hrtx-stock-earnings-heron-therapeutics-for-q1-of-2024/">HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024

Heron Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

Analyst Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) and keeping the price target at $5.00. S...

Heron Therapeutics: A Strong Buy on Surging Sales and Strategic Partnerships

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AN2 Therapeutics, Inc. (ANTX – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)

An announcement from Heron Therapeutics (HRTX) is now available. Heron Therapeutics, Inc. has announced the submission of a Prior Approval Suppleme...

Heron Therapeutics Submits ZYNRELEF® Supplement to FDA

Northland Securities analyst Carl Byrnes maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) today and set a price target of $9....

Northland Securities Reaffirms Their Buy Rating on Heron Therapeutics (HRTX)

Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves

Heron Therapeutics announces acceptance of PAS application for dual-acting anesthetic

Heron Therapeutics (HRTX) just unveiled an announcement. Heron Therapeutics, Inc. recently announced that the FDA has received its application for ...

Heron Therapeutics' ZYNRELEF Review Date Set by FDA

ANTX

Biotech Finds Mid-Week Success Following Q4 Earnings Release

Press Releases

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Heron Therapeutics

Heron Therapeutics (HRTX) Forecast

Heron Therapeutics (NASDAQ:HRTX) Stock, Quote.Headers.trade-ideas